Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect
- 24 September 2004
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 499 (3), 219-228
- https://doi.org/10.1016/j.ejphar.2004.07.063
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sproutingAPMIS, 2003
- Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastasesCancer, 2000
- Angiogenesis New Targets for the Development of Anticancer ChemotherapiesCurrent Pharmaceutical Design, 2000
- Inhibition of Endothelial Cell Migration, Intercellular Communication, and Vascular Tube Formation by Thromboxane A2Journal of Biological Chemistry, 1999
- Antiangiogenic potential of camptothecin and topotecanCancer Chemotherapy and Pharmacology, 1999
- Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction PathwayJournal of Biological Chemistry, 1998
- Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurityNature Medicine, 1995
- Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospectsJournal of Molecular Medicine, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994